Articles by Anna Rose Welch

31. FDA News Roundup: AstraZeneca, Pfizer, AbbVie, Actavis, And More 4/24/2015

    What FDA decisions did you miss this week?

32. Leadership Lessons From 23andMe's Jump Into Drug Discovery 4/17/2015

    23andMe has been the center of attention quite a bit recently — not only because of its high profile partnerships with Pfizer and Genentech, but also because of the recent FDA approval of its carrier test for Bloom Syndrome. However, perhaps the biggest news for the company as of late was the announcement it is jumping into the drug discovery space.

33. FDA News Roundup: Teva, AstraZeneca, Amgen, Medicines Company, And More 4/17/2015

    What FDA decisions did you miss this week?

34. Will China Ever See Its Own Blockbuster Drug? 4/10/2015

    It’s no secret that China is trying to become an attractive destination for companies looking to hold clinical trials and develop and manufacture drugs overseas. However, I’m also curious about what we can and should expect from the country in terms of innovation — especially when it comes to developing its own high profile drug.

35. FDA News Roundup: Novo Nordisk, AstraZeneca, Merck, And More 4/10/2015

    What FDA decisions did you miss this week?

36. Where Did The Biobetters Buzz Go? 4/2/2015

    The past few weeks, it seems the word on everyone’s tongue — including my own — has been biosimilars. Since the approval of Novartis’ Zarzio in the U.S., there’s been a lot of discussion and speculation about how this important approval will affect current blockbusters on the market and who will enter the space next. But I’m left with another question: What happened to the buzz over biobetters?

37. FDA News Roundup: AstraZeneca, Teva, Amgen, And More 4/2/2015

    What regulatory decisions did you miss this week?

38. What Is The Reason For Uneven Gender Roles In Pharma Leadership? 3/27/2015

    About a month ago, Sanofi put an end to its several-month-long search for a new CEO by selecting Bayer’s Olivier Brandicourt. The day the company announced this move, I published a blog questioning why it’s so often expected that CEO positions in pharma (and really in any industry) will most likely be held by men. This question arose after finding a survey that revealed a majority of respondents believed the position would be taken by a male.

39. FDA News Roundup: Merck, Actavis, Vertex, And More 3/20/2015

    What FDA decisions did you miss this week?
     

40. Can These 3 Anti-Counterfeiting Methods Protect Pharma's Supply Chain? 3/13/2015

    The Drug Quality and Security Act (DQSA) is on the minds of many these days as companies make the necessary investments and launch initiatives to ensure regulatory compliance and supply chain integrity. However, I’ve also been taking note of some of the ways companies and researchers in the industry have been trying to protect pharma products from counterfeiters and keep patients from being fooled by counterfeiters’ increasingly sophisticated tricks.